Miriam Molina Arcas

The Francis Crick Institute

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (14)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (9)

Mihaela Angelova

The Francis Crick Institute

UNITED KINGDOM

View details

Martin Forster

University College London

UNITED KINGDOM

View details

Gavin Kelly

The Francis Crick Institute

UNITED KINGDOM

View details

Philip East

Deputy Head

The Francis Crick Institute

UNITED KINGDOM

View details

Alan Pittman

University College London

UNITED KINGDOM

View details

Michael Howell

The Francis Crick Institute

UNITED KINGDOM

View details

Filippo Prischi

Senior Lecturer

King’s College London

UNITED KINGDOM

View details

Nicolai Birkbak

Aarhus University

DENMARK

View details

Gary Middleton

Professor of Medical Oncology

University of Birmingham

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Miriam Molina Arcas

Research Interests

Explore related searches

Contact this professor

Articles (14)

Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses.

Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade.

CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer.

Exploiting the therapeutic implications of KRAS inhibition on tumor immunity.

Antibodies against endogenous retroviruses promote lung cancer immunotherapy.

Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy

Characterisation of a cyclic peptide that binds to the RAS binding domain of phosphoinositide 3-kinase p110α.

An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations.

Therapeutic KRAS<sup>G12C</sup> inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.

The Potency of a <i>KRAS</i> Silent Variant.

Inherited duplications of PPP2R3B predispose to nevi and melanoma via a C21orf91-driven proliferative phenotype

Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry.

Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer.

Drugging the Undruggable: Advances on RAS Targeting in Cancer.

Collaborators (9)

Mihaela Angelova

Martin Forster

Gavin Kelly

Philip East

Alan Pittman

Michael Howell

Filippo Prischi

Nicolai Birkbak

Gary Middleton

Make your next move.